Personalized vaccine with immunotherapy for non-small cell lung cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have non-small cell lung cancer that has been surgically removed but did not respond fully to pre-surgery treatment, or your cancer has spread or returned after first-line treatment.
- You are willing to provide a tumor tissue sample and blood samples for genetic testing.
- You are generally in good health (able to care for yourself and up and about).
- You do not have certain genetic mutations (like EGFR or ALK) that already have approved targeted drugs.
- You have no active autoimmune disease or serious heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine made from your tumor's unique mutations. It is given after surgery to try to train your immune system to fight any remaining cancer cells, with the goal of preventing the cancer from coming back.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a personalized cancer vaccine, given alone or with an immunotherapy drug called toripalimab, in people with non-small cell lung cancer (NSCLC) who have had surgery and are getting adjuvant therapy (treatment to prevent the cancer from coming back). The goal is to see if the vaccine is safe and may help the immune system fight any remaining cancer cells.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.